Rigel Pharmaceuticals, Inc. (RIGL) Earnings History
Annual and quarterly earnings data from 1999 to 2025
Loading earnings history...
RIGL EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RIGL Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 93.3% | 42.6% | 124.7% |
| 2024 | 89.6% | 13.5% | 9.8% |
| 2023 | 93.9% | -17.5% | -21.5% |
| 2022 | 98.5% | -46.2% | -48.7% |
| 2021 | 99.3% | -8.4% | -12.0% |
Download Data
Export RIGL earnings history in CSV or JSON format
Free sign-in required to download data
Rigel Pharmaceuticals, Inc. (RIGL) Earnings Overview
As of May 8, 2026, Rigel Pharmaceuticals, Inc. (RIGL) reported trailing twelve-month net income of $364M, reflecting +1867.7% year-over-year growth. The company earned $18.50 per diluted share over the past four quarters, with a net profit margin of 124.7%.
Looking at the long-term picture, RIGL's historical earnings data spans multiple years. The company achieved its highest annual net income of $367M in fiscal 2025, representing a new all-time high.
Rigel Pharmaceuticals, Inc. maintains industry-leading profitability with a gross margin of 93.3%, operating margin of 42.6%, and net margin of 124.7%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including PRTA (-$151M net income, -2520.6% margin), FOLD (-$27M net income, -4.3% margin), RARE (-$609M net income, -85.4% margin), RIGL has outperformed on profitability metrics. Compare RIGL vs PRTA →
RIGL Earnings vs Peers
Earnings metrics vs comparable public companies
RIGL Historical Earnings Data (1999–2025)
27 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $367M | +1999.1% | $125M | $19.48 | 124.7% | 42.6% |
| 2024 | $17M | +169.7% | $24M | $0.99 | 9.8% | 13.5% |
| 2023 | -$25M | +57.2% | -$20M | $-1.44 | -21.5% | -17.5% |
| 2022 | -$59M | -227.0% | -$56M | $-3.40 | -48.7% | -46.2% |
| 2021 | -$18M | +39.8% | -$12M | $-1.10 | -12.0% | -8.4% |
| 2020 | -$30M | +55.3% | -$29M | $-1.80 | -27.4% | -26.7% |
| 2019 | -$67M | +5.6% | -$69M | $-4.00 | -112.2% | -116.5% |
| 2018 | -$70M | +9.6% | -$73M | $-4.40 | -158.3% | -163.3% |
| 2017 | -$78M | -12.7% | -$80M | $-6.17 | -1739.3% | -1775.6% |
| 2016 | -$69M | -34.5% | -$70M | $-7.33 | -339.6% | -342.2% |
See RIGL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RIGL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RIGL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRIGL — Frequently Asked Questions
Quick answers to the most common questions about buying RIGL stock.
Is RIGL growing earnings?
RIGL EPS is $18.50, with earnings growth accelerating to +1867.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $364M.
What are RIGL's profit margins?
Rigel Pharmaceuticals, Inc. net margin is +124.7%, with operating margin at +42.6%. Above-average margins indicate pricing power.
How consistent are RIGL's earnings?
RIGL earnings data spans 1999-2025. The accelerating earnings trend is +1867.7% YoY. Historical data enables comparison across business cycles.